adaura study demonstrates promising efficacy for osimertinib in egfr-mutant nsclc
Published 3 years ago • 513 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:23
flaura trial demonstrates efficacy in egfr-positive lung cancer
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
1:42
adaura: the benefit of adjuvant osimertinib
-
2:06
adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
4:24
reflections on the adaura study
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers